Company Update (NYSE:PFE): Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age

[Business Wire] – Pfizer Inc. announced today the top-line results from a Phase 3B study evaluating the 24-month efficacy of GENOTROPIN® on the height in small-for-gestational-age children 24-30 months old. Read more on . . . → Read More: Company Update (NYSE:PFE): Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age Similar Articles: Pfizer Inc (NYSE:PFE) | Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts Market Update (NYSE:PFE): Pfizer Launches 2013 Integrated Annual Review Company Update – Biogen Idec Inc. (NASDAQ:BIIB) – Sobi’s partner Biogen Idec to present phase 3 data on prolonged half-life of Haemophilia candidates in young children at annual ASH meeting